Home
Clinical Trials
ALT-FLOW II Trial of the Edwa...

ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System

Last Updated: 2025-08-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-01

Study Completion Date

2030-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multi-center, randomized, sham-controlled, double-blinded (participant and outcomes assessor) clinical trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Exploratory Study of the Edwards APTURE Transcatheter Shunt System (ALT-FLOW Canada)

NCT04000607

Heart Failure

ACTIVE_NOT_RECRUITING NA

Alleviate-HF-2 Study

NCT04838353

Heart Failure

COMPLETED NA

ALTERRA Post-Approval Study

NCT05378386

Pulmonary Valve Insufficiency Complex Congenital Heart Defect Tetralogy of Fallot +2 more

ACTIVE_NOT_RECRUITING

Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE)

NCT03016975

Functional Mitral Regurgitation Mitral Regurgitation Mitral Insufficiency

TERMINATED NA

Cardiac Output Pulmonary Arterial Catheter Compared to FloWave™ 1000

NCT00665301

Congestive Heart Failure Ischemic Cardiomyopathy Mitral Valve Prolapse +3 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objectives of this trial are to assess the safety, performance, and effectiveness of the Edwards APTURE transcatheter shunt system when used for the treatment of patients with heart failure with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction (LVEF \>40%) who remain symptomatic despite guideline-directed medical therapy (GDMT)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APTURE shunt + medical therapy

Group Type EXPERIMENTAL

Edwards APTURE transcatheter shunt system

Intervention Type DEVICE

Treatment with APTURE shunt

Sham + medical therapy

Group Type SHAM_COMPARATOR

Sham procedure

Intervention Type DIAGNOSTIC_TEST

CS angiography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Edwards APTURE transcatheter shunt system

Treatment with APTURE shunt

Intervention Type DEVICE

Sham procedure

CS angiography

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Symptomatic heart failure

1. A primary diagnosis of HFmrEF or HFpEF (LVEF \> 40%), and
2. NYHA class II to ambulatory NYHA class IV (IVa), and
3. Documentation of at least one of the following from the date of initial informed consent or date of enrollment:

i. Within the prior 12 months, EITHER:

* HF hospital admission (with HF as the primary or secondary diagnosis)
* Treatment with intravenous (IV) or intensification of oral diuretics for HF

ii. Within the prior 6 months, EITHER:

* BNP value \> 35 pg/ml in normal sinus rhythm (NSR) or paroxysmal atrial fibrillation (AF)
* BNP \> 125 pg/ml for permanent or long-term persistent AF
* NT-proBNP \> 125 pg/ml in NSR or paroxysmal AF
* NT-proBNP \> 375 pg/ml for permanent or long-term persistent AF d. There is objective evidence of cardiogenic pulmonary congestion based on hemodynamic criteria obtained by right heart catheterization (RHC) at exercise, and confirmed by hemodynamics core lab as: As measured at end-expiration, pulmonary capillary wedge pressure (PCWP) at ≥ 20 Watts exercise (PCWP ≥ 20W) is elevated to ≥ 25 mmHg and exceeds \[the corresponding\] right atrial pressure (RAP) by ≥ 8 mmHg • In the judgment of the treating physician and the Central Screening Committee the patient is on GDMT for HFpEF/HFmrEF for \>30 days prior to screening and baseline assessments, that is expected to be maintained without change for 6 months.

Exclusion Criteria

* Severe heart failure defined as one or more of the below:

1. ACC/AHA/ESC Stage D HF, non-ambulatory NYHA Class IV HF
2. If Body Mass Index (BMI) \< 30, cardiac index \< 2.0 L/min/m2
3. If BMI ≥ 30, cardiac index \< 1.8 L/min/m2
4. Inotropic infusion (continuous or intermittent) within the past 6 months
5. Patient is on the cardiac transplant waiting list
6. Prior diagnosis of HF with reduced ejection fraction (HFrEF), including patients with improvement in LVEF to \> 40%
* Valve disease:

1. Degenerative mitral regurgitation \> moderate
2. Functional or secondary mitral valve regurgitation defined as grade \> moderate
3. Mitral stenosis \> mild
4. Primary or secondary tricuspid valve regurgitation defined as grade \> moderate
5. Aortic valve disease defined as aortic regurgitation grade \> moderate or aortic stenosis \> moderate
* More than mild right ventricular (RV) dysfunction as determined by the echo core lab, taking into account the following available parameters:

1. Tricuspid annular plane systolic excursion (TAPSE) \<1.4 cm, or
2. RV size ≥ LV size
3. Right ventricular ejection fraction (RVEF) \< 35%; or
4. Imaging or clinical evidence of congestive hepatopathy
* Mean right atrial pressure (mRAP) \> 15 mmHg at rest
* Pulmonary vascular resistance (PVR) ≥ 5.0 WU
* BMI ≥ 45
* Myocardial infarction (MI) and/or any therapeutic invasive, non-valvular cardiovascular procedure within past 3 months or current indication for coronary revascularization
* Stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT) or pulmonary embolus within the past 6 months
* Renal insufficiency as determined by creatinine (sCr) level \> 2.5 mg/dL or estimated glomerular filtration rate (eGFR) \< 25ml/min/1.73 m2 by CKD-Epi equation; or currently requiring dialysis
* Performance of the six-minute walk test (6MWT) with a distance \< 50m OR \> 450m
* Active endocarditis or infection requiring intravenous antibiotics within 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers